Imiphumela evela esivivinyweni esikhulu somtholampilo ibonisa ukuthi ukwengeza i-blinatumomab (Blincyto) ekwelapheni abantu abane I-acute lymphoblastic leukemia (YONKE) abasekuxolelweni, ngisho noma zingekho izimpawu zesifo sabo, zingabasiza baphile isikhathi eside.
Ocwaningweni, ukunikeza i-blinatumomab kanye nokwelashwa ngamakhemikhali kwenze abantu abanomdlavuza ababengene ekuxolelweni baphile isikhathi eside kunalabo abathole i-chemotherapy kuphela, okuwukwelashwa okujwayelekile kwamanje. Iziguli ovivinyweni zazingezona nje kuphela ukuxola, kodwa kwakungekho uphawu lomdlavuza wazo. Lokhu kubizwa ngokuba nokuba ubuncane besifo esiyinsalela (MRD) -negative BONKE.
Imiphumela yocwaningo yaboniswa emhlanganweni waminyaka yonke we-American Society of Hematology (ASH) eNew Orleans ngoDisemba 2022.
In 2018, the Food and Drug Administration (FDA) cleared i-blinatumomab to treat people with MRD-positive ALL who were in remission but still showed signs of cancer during follow-up tests. Even though recurrences after remission are always possible, people with MRD-positive ALL have a higher chance of their cancer coming back after their first treatment than those who do not have MRD.
Emhlanganweni we-ASH, imiphumela ikhonjiswe kubantu ababengenayo MRD ngemva kwemithi yabo yokuqala.
Eminyakeni engu-3.5 ngemva kokuqala ukwelashwa kwangemuva kokuxolelwa, ama-83% eziguli ezalashwa nge-blinatumomab kanye nokwelashwa ngamakhemikhali zazisaphila, kuyilapho zingama-65% kuphela eziguli ezelashwe nge-chemotherapy zizodwa ezazisaphila.
I-Blinatumomab isebenza kahle ku-MRD-negative BONKE futhi
B-cell ALL is the most common type of ALL in both adults and children. It is a type of umdlavuza wegazi that spreads quickly and is very dangerous. Chemotherapy is the standard treatment, and it often leads to remission. However, a lot of people get sick again, even if tests done after treatment show no signs of disease.
Izidakamizwa ze-Immunotherapy zibonise isithembiso njengendlela yokwelapha umdlavuza ngemva kokuba usuphelile futhi yehlisa ingozi yokubuya.
Uhlobo lwe immunotherapy called a bispecific T-cell engager (BiTE) is what blinatumomab is. It sticks to both T cells and cancer cells at the same time. This makes it easy for T cells to find and kill the cancer cell by bringing them closer together. The drug, which is given through an IV, has been shown to be more effective than chemotherapy at treating B-ALL that has come back in children and young adults who have already been treated for it.
Lolu cwaningo, oluqhutshwa yi-ECOG-ACRIN Cancer Research Group ngosizo lwe-NCI, lwaqala ngo-2013 ukubona ukuthi i-blinatumomab ingabasiza yini abantu abasanda kutholakala bene-B-cell ALL.
Ngisho noma abantu abangama-488 baba nengxenye ocwaningweni sebebonke, imiphumela ekhonjiswe ku-ASH yayingeyabantu abangu-224 kuphela ababexolelwe futhi bengenayo i-MRD ngemuva kwemithi yokuqala evamile yokwelapha ngamakhemikhali. Iziguli zanikezwa i-chemotherapy eyengeziwe ngaphezu kwe-blinatumomab noma i-chemotherapy nje. Khona-ke, zonke izifundo zithole ukwelashwa ngamakhemikhali njalo ngemva kwezinyanga eziyisithupha iminyaka engu-2.5. Abanye abantu baphinde bathola ukufakelwa komnkantsha wamathambo uma udokotela wabo ecabanga ukuthi kungcono kakhulu.
Akugcinanga nje ngokungeza i-blinatumomab ku-chemotherapy ngcono impilo yonke, kodwa kuphinde kwenza iziguli ziphile isikhathi eside ngaphandle komdlavuza wazo ukubuya uma kuqhathaniswa nalabo abathole ukwelashwa ngamakhemikhali kuphela.
UDkt. Litzow uthe akekho noyedwa kubantu abathatha i-blinatumomab owaba nemiphumela emibi engalindelekile. Eminye yemiphumela evame kakhulu ye-blinatumomab imfiva, ukusabela ekufakweni, ubuhlungu bekhanda, izifo, ukundindizela, kanye nokubanda.
